雌激素硫酸转移酶（SULT1E1）在乳腺癌中的表达及临床生物学意义
摘要
目的:探讨雌激素硫酸转移酶(SULT1E1)在乳腺癌中的表达,及其与雌激素受体和临床病理学特征的关系。
方法:采用逆转录多聚酶链式反应( RT-PCR)以及免疫组化方法分别检测37例乳腺癌组织、37例癌旁正常乳腺组织及10例乳腺纤维腺瘤组织的SULT1E1mRNA及蛋白的表达;免疫组化法检测乳腺癌组织雌激素受体( ER)的蛋白表达。
结果:SULTlElmRNA在乳腺癌组织、癌旁正常乳腺组织和乳腺纤维腺瘤组织中的表达分别为(0.47±0.30)、(0.69±0.30)*、(0.74±0.60)﹟(*和﹟分别和乳腺癌组比较p<0.01)。
SULTlElmRNA在早期(Ⅰ+Ⅱ期)和局部晚期(IIIA+IIIB+IIIC)乳腺癌的表达分别为(0.45±0.22)、(0.52±0.5) , (P>0.05) ;在高分化和低分化乳腺癌的表达分别为(0.47±0.17)、(0.46±0.31),(P>0.05);在直径<3cm组和直径≥3cm组乳腺癌的表达为(0.49±0.27)、(0.43±0.33),(P>0.05);在淋巴结转移组和无淋巴结移组乳腺癌表达分别为(0.48±0.26)、(0.45±0.33),(P>0.05);绝经前后乳腺癌患者表达分别为(0.44±0.27)、(0.48±0.32),(P>0.05)。
ER阳性和ER阴性乳腺癌中SULTlElmRNA的表达分别为(0.37±0.17)、(0.47±0.30),(P <0.05)。ER阳性乳腺癌亚组中,直径<3cm组和直径≥3cm组SULTlElmRNA的表达为(0.45±0.16)、(0.29±0.16),(P<0.05);淋巴结转移组和无淋巴结转移组的SULTlElmRNA表达分别为(0.30±0.15)、(0.44±0.17),(P>0.05)。
SULTlEl蛋白均表达于细胞浆,在乳腺癌组织、癌旁正常乳腺组织和乳腺纤维腺瘤组织的表达率分别为48.6%(18/37)、81.1%(30/37)*、90%(9/10)
,(*/
分别和乳腺癌组比较p<0.01)。ER阳性和阴性乳腺癌的SULTlEl蛋白表达率分别为为33.3% (7/21)、68.75%(11/16),(P<0.05)。ER阳性乳腺癌亚组中,SULTlEl蛋白在直径<3cm组和直径≥3cm组的表达率分别为66.7% (12/18)、31.6% (6/19),(P<0.05);淋巴结转移组和无淋巴结转移组分别为38.9%(7/18)、57.9%(11/19)(p>0.05)。
结论:1、SULTlEl蛋白在正常人乳腺组织、乳腺纤维腺瘤组织和乳腺癌组织均表达于细胞浆。
2、乳腺癌SULTlElmRNA和蛋白的表达均低于癌旁正常乳腺组织。ER阳性乳腺癌SULTlEl mRNA和蛋白的表达均低于ER阴性乳腺癌和癌旁正常乳腺组织,ER阴性乳腺癌SULT1E1表达与癌旁正常乳腺组织相仿。提示SULTlElmRNA和蛋白表达下降可能和激素敏感型乳腺癌的发生有关。
Objective: To investigate estrogen sulfate transferase (SULT1E1) expression in breast cancer, and the relationship between estrogen receptor and its clinicopathological features.
Methods:Reverse transcription polymerase chain reaction (RT-PCR) and immunohisto- chemistry were used to detect estrogen sulfate transferase (SULT1E1) mRNA and protein expression, and immunohistochemical method to detect breast cancer in estrogen receptor (ER) protein expression.
The expression of SULTlElmRNA in breast cancer tissue, adjacent normal breast tissue and breast fibroadenoma tissues were (0.47±0.30), (0.69±0.30) *, (0.74±0.60)# respectively (* and #, were campared to the breast cancer group respectively, p <0.01). The expression of SULTlElmRNA in the early (Ⅰ+Ⅱ) breast cancer (0.45±0.22) and in advanced (IIIA + IIIB + IIIC) breast cancer (0.52±0.5)(P> 0.05). The expression of SULTlElmRNA in well and poorly differentiated breast cancer in the relative levels were 0.47±0.17; 0.46±0.31,the differences had no stastistical significance (P> 0.05). The expression of SULTlElmRNA in diameter <3cm group of breast cancer (0.49±0.27),in diameter> 3cm group expression (0.43±0.33)(P> 0.05). The expression of SULTlElmRNA in breast cancer With lymph node metastasis (0.48±0.26) and the shift of breast cancer without lymph node (0.45±0.33) compared to no significant difference (P> 0.05). The expression of SULTlElmRNA in premenopausal and postmenopausal breast cancer patients were (0.44±0.27), (0.48±0.32)respectively(P> 0.05).
Breast cancer, adjacent normal breast tissue and fibroadenoma tissue SULTlEl protein expression rates were 48.6% (18/37), 81.1% (30/37) * 90% (9 / 10)
, * respectively. and * was compared to the breast cancer p <0.01,
was compared to the adjacent normal breast tissue P> 0.05).
SULTlEl protein in the ER receptor-positive breast cancer rate (7 / 21 33.3%), was lower than the ER receptor negative breast cancer (11/16 68.75%), the difference had stastistical significance (P <0.05). SULTlEl protein expression of breast cancer with lymph node metastasis (7 / 18 38.9%) and the shift of breast cancer without lymph node metastasis (11/19 57.9%) compared to no statistically significant difference (p> 0.05).The SULTlEl protein expression in breast cancer tissue with tumor diameter> 3cm (6 / 19 31.6%)was lower than the tumor diameter <3cm (12/18 66.7%), (P <0.05).
Conclusion: 1.SULTlEl protein in normal breast tissue, breast fibroadenoma tissue and cancer tissue expressed in the cytoplasm.
The expression of SULTlElmRNA and protein in breast cancer are lower than normal breast tissue, the differences had stastistical significance (P <0.05). The SULTlElmRNA and protein levels of ER-positive breast cancer are relatively lower than the ER-negative breast cancer, the expression of SULTlElmRNA and protein in ER-negative breast cancer tissue and normal breast tissue are similar. Tip SULTlElmRNA and decreased protein expression may be related to the occurrence of the hormone-sensitive breast cancer .
方法:采用逆转录多聚酶链式反应( RT-PCR)以及免疫组化方法分别检测37例乳腺癌组织、37例癌旁正常乳腺组织及10例乳腺纤维腺瘤组织的SULT1E1mRNA及蛋白的表达;免疫组化法检测乳腺癌组织雌激素受体( ER)的蛋白表达。
结果:SULTlElmRNA在乳腺癌组织、癌旁正常乳腺组织和乳腺纤维腺瘤组织中的表达分别为(0.47±0.30)、(0.69±0.30)*、(0.74±0.60)﹟(*和﹟分别和乳腺癌组比较p<0.01)。
SULTlElmRNA在早期(Ⅰ+Ⅱ期)和局部晚期(IIIA+IIIB+IIIC)乳腺癌的表达分别为(0.45±0.22)、(0.52±0.5) , (P>0.05) ;在高分化和低分化乳腺癌的表达分别为(0.47±0.17)、(0.46±0.31),(P>0.05);在直径<3cm组和直径≥3cm组乳腺癌的表达为(0.49±0.27)、(0.43±0.33),(P>0.05);在淋巴结转移组和无淋巴结移组乳腺癌表达分别为(0.48±0.26)、(0.45±0.33),(P>0.05);绝经前后乳腺癌患者表达分别为(0.44±0.27)、(0.48±0.32),(P>0.05)。
ER阳性和ER阴性乳腺癌中SULTlElmRNA的表达分别为(0.37±0.17)、(0.47±0.30),(P <0.05)。ER阳性乳腺癌亚组中,直径<3cm组和直径≥3cm组SULTlElmRNA的表达为(0.45±0.16)、(0.29±0.16),(P<0.05);淋巴结转移组和无淋巴结转移组的SULTlElmRNA表达分别为(0.30±0.15)、(0.44±0.17),(P>0.05)。
SULTlEl蛋白均表达于细胞浆,在乳腺癌组织、癌旁正常乳腺组织和乳腺纤维腺瘤组织的表达率分别为48.6%(18/37)、81.1%(30/37)*、90%(9/10)
,(*/
分别和乳腺癌组比较p<0.01)。ER阳性和阴性乳腺癌的SULTlEl蛋白表达率分别为为33.3% (7/21)、68.75%(11/16),(P<0.05)。ER阳性乳腺癌亚组中,SULTlEl蛋白在直径<3cm组和直径≥3cm组的表达率分别为66.7% (12/18)、31.6% (6/19),(P<0.05);淋巴结转移组和无淋巴结转移组分别为38.9%(7/18)、57.9%(11/19)(p>0.05)。
结论:1、SULTlEl蛋白在正常人乳腺组织、乳腺纤维腺瘤组织和乳腺癌组织均表达于细胞浆。
2、乳腺癌SULTlElmRNA和蛋白的表达均低于癌旁正常乳腺组织。ER阳性乳腺癌SULTlEl mRNA和蛋白的表达均低于ER阴性乳腺癌和癌旁正常乳腺组织,ER阴性乳腺癌SULT1E1表达与癌旁正常乳腺组织相仿。提示SULTlElmRNA和蛋白表达下降可能和激素敏感型乳腺癌的发生有关。
Objective: To investigate estrogen sulfate transferase (SULT1E1) expression in breast cancer, and the relationship between estrogen receptor and its clinicopathological features.
Methods:Reverse transcription polymerase chain reaction (RT-PCR) and immunohisto- chemistry were used to detect estrogen sulfate transferase (SULT1E1) mRNA and protein expression, and immunohistochemical method to detect breast cancer in estrogen receptor (ER) protein expression.
The expression of SULTlElmRNA in breast cancer tissue, adjacent normal breast tissue and breast fibroadenoma tissues were (0.47±0.30), (0.69±0.30) *, (0.74±0.60)# respectively (* and #, were campared to the breast cancer group respectively, p <0.01). The expression of SULTlElmRNA in the early (Ⅰ+Ⅱ) breast cancer (0.45±0.22) and in advanced (IIIA + IIIB + IIIC) breast cancer (0.52±0.5)(P> 0.05). The expression of SULTlElmRNA in well and poorly differentiated breast cancer in the relative levels were 0.47±0.17; 0.46±0.31,the differences had no stastistical significance (P> 0.05). The expression of SULTlElmRNA in diameter <3cm group of breast cancer (0.49±0.27),in diameter> 3cm group expression (0.43±0.33)(P> 0.05). The expression of SULTlElmRNA in breast cancer With lymph node metastasis (0.48±0.26) and the shift of breast cancer without lymph node (0.45±0.33) compared to no significant difference (P> 0.05). The expression of SULTlElmRNA in premenopausal and postmenopausal breast cancer patients were (0.44±0.27), (0.48±0.32)respectively(P> 0.05).
Breast cancer, adjacent normal breast tissue and fibroadenoma tissue SULTlEl protein expression rates were 48.6% (18/37), 81.1% (30/37) * 90% (9 / 10)
, * respectively. and * was compared to the breast cancer p <0.01,
was compared to the adjacent normal breast tissue P> 0.05).
SULTlEl protein in the ER receptor-positive breast cancer rate (7 / 21 33.3%), was lower than the ER receptor negative breast cancer (11/16 68.75%), the difference had stastistical significance (P <0.05). SULTlEl protein expression of breast cancer with lymph node metastasis (7 / 18 38.9%) and the shift of breast cancer without lymph node metastasis (11/19 57.9%) compared to no statistically significant difference (p> 0.05).The SULTlEl protein expression in breast cancer tissue with tumor diameter> 3cm (6 / 19 31.6%)was lower than the tumor diameter <3cm (12/18 66.7%), (P <0.05).
Conclusion: 1.SULTlEl protein in normal breast tissue, breast fibroadenoma tissue and cancer tissue expressed in the cytoplasm.
The expression of SULTlElmRNA and protein in breast cancer are lower than normal breast tissue, the differences had stastistical significance (P <0.05). The SULTlElmRNA and protein levels of ER-positive breast cancer are relatively lower than the ER-negative breast cancer, the expression of SULTlElmRNA and protein in ER-negative breast cancer tissue and normal breast tissue are similar. Tip SULTlElmRNA and decreased protein expression may be related to the occurrence of the hormone-sensitive breast cancer .
引文
[1] Sasano H. Functional pathology of human ovarian steroidogenesis: normal cyclingovary and steroid-producing neoplasms. Endocr Pathol 1994(5): 81-89.
[2] Vihko R, and Apter D. Endogenous steroids in the pathophysiology of breast cancer. CRC. Crit. Rev. Oncol. Hematol, 1989(9): 1–16.
[3] Rose C, Thorpe SM, Mouridsen, H T, Andersen J A,et al. Anti-oestrogen retreatment of post menopausal women with primary high risk breast cancer. Breast Cancer Res. Treat, 1983(3): 77–84.
[4] Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved inestrogen formation and transformation in human breast cancer. Steroid Biochem Mol Biol 2005,93(2-5):221-236.
[5] Evans TR,Rowlands MG,Law M,et al. Intratumoral oestrone sulphatas activity as a prognostic marker in human breast carcinoma .Br J Cancer 1994,69(3):555-561
[6] Evans TR, Rowlands MG, Powles TJ.Post menopausal estrogen synthesis and metabolism:alterations caused by aromatase inhibitors used for the treatment of breast cancer. Steroid Biochem,1990,35(3-4):355-366
[7] Utsumi T, Yoshimura N, Takeuehi S, et al.Elevated steroid sulfatase expression in breast cancers.Steroid Biochem Mol Biol,2000,73(3-4):141-145.
[8] Pasqualini JR.Differential effects of progestins on breast tissue enzymes. Maturitas,2003,46(Suppl 1):S45-54
[9] Nakata, Takashima S,Shiotsu Y. Role of steroid sulfatase in local Formation of estrogen in post-menopausal breast cancer patients.Steroid Biochem Mol Biol,2003,86(3-5):455-460
[10] Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, andestrone sulfate and evaluation of sulfatase and aromatase activities in pre- andpostmenopausal breast cancer patients. Clin Endocrinol Metab 1996 ;81(4):1460-1464.
[11] Luu-the V, Tremblay P, Labrie F. Characterization of type 12 17beta-hydroxysteroiddehydrogenase, an isoform of type 3 17beta-hydroxysteroiddehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006;20(2):437-443.
[12] Suzuki T, Moriya T, Ariga N, et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br Cancer 2000;82(3):518-523.
[13] Song D, Liu G, Luu-the V, et al.Expression of aromatase and 17beta-hydroxysteroiddehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. Steroid Biochem Mol Biol 2006;101(2-3):136-144.
[14] Miyoshi Y, Ando A,Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts Poor Prognosis in Patients with estrogen receptor-Positive breast Cancer. Clin Cancer ReS,2003;9(6):2288-2293.
[15] Foster PA,Chander SK,NewmanSP,et al. A new therapeutic strategy against hormone-dependent breast cancer:the pre-clinical development of a dual aromatase and sulfatase inhibitor .Clin Cancer Res, 2008,14(20):6469-6477
[16] Suzuki M,Ishida H,Shiotsu Y,et al.Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. Steroid Biochem Mol Biol 2009;113(3-5):195-201.
[17] Adajei AA , weinshibum RM . Catecholestrogen sulfation : possible role in carcinogenesis.Biochem Biophys Res Common.2002;292:
[18] Falany JL,MacrinaN,Falany CN.Regulation of MCF-7 breast cancer cell growth byβ-estrdiol sulfation.Breast Cancer RES Tr.2002;74:167-176
[19] YingHUI, ShinYASUDA, Ming-Yin LIU, et al.On the Sulfationand Methylation of Cateehol estrogens in Human Mammary epithelial Cells and Breast Cancer Cells.Bio Pharm.Bull.2008;4(3 1):769-773
[20] Schrag ML,Donghui Cui,Rushmore T.Het al.Sulfotransferase lEl is a low Km isoform mediating the 3-0-sulfation of ethinyl. Drug Metabolism and Disposition. 2004,32:1299-1303.
[21] Wild MJ, Rudland PS, Back DJ. Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal ( Huma 7 ) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.J steriod BiocheMol Biol,1991,39:535-543
[22] Chetrite, G., Le Nestour, E., and Pasqualini, J. R. Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020). Steroid Biochem. Mol. Biol.,1998;66: 295–302,.
[23] Falany, JL, and Falany, CN, Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res. 1996;56: 1551–1555.
[24] Takashi Suzuki, Taisuke Nakata, Yasuhiro Miki, et al. Estrogen Sulfotransferase and Steroid Sulfatase in Human Breast Carcinoma.Cancer Res 2003;63:2762-2770.
[25] Pasqualini JR, Chetrite GC, Blacker, et al.Concentrations of estrone,estradioland estrone sulfate and evaluation of sulfatase and aomatase aetivities in Pre-and-Post menopausal breast cancer patients. Clin Endoerinol Metab.1996;81:1460-1464
[26] BulunSE, Yangs, FangZ, et al.Estrogen Production and metabolism endometriosis Mol Hum Re Poul.2002;8(12)1103-1110
[1]、Yang L.Parkin DM,Ferlav J,et al.Eimates of cancer incidence in China for 2000 and projections for 2005 [J].Cancer Epidemiol Biomarkers Prev,2005,14(1):243-250.
[2]、陈剑英,张波,王国斌,等.乳腺癌中雌激素诱导的细胞增殖与有丝分裂素激活蛋白激酶活性的关系.中华外科杂志,2004,42(22):1363-1366.
[3]、Pozzi S,Benedusi V,Maggi A,et al.Estrogen action in neuro—protection and brain inflammation.Ann N Y Acad Sei,2006,1089:302-323.
[4]、Strehlow K,Rotter S,Wassmann S,et al.Modulation of antioxidant enzyme expression and function by estrogen. Circ Res,2003,93(2):170-177.
[5]、Benvenuti S,Luciani P,Vannelli GB,et al.Estrogen and selectire estrogen receptor modulators exert neur0pr0tective effects and stimulate the expression of selective Alzheim er's disease indicator1,a recently discovered antiapoptotie gene,in hum an neuroblast long—term cell cultures.Clin Endocrinol Metab,2005,90(3):1775-1782.
[6]、Misiti S,Nanni S,Fontemaggi G,et al.Induction of hTERT expression and telom erase activity by estrogens in human ovary epithelium cells.Mol Cell Biol,2000,20(11):3764—3771.
[7]、Geisler J.Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. Steroid Biochem Mol Biol,2003,86(3一5):245一253.
[8]、Reed MJ,Purohit A,Woo LW,et al.Steroid sulfatase:molecular biology,regulation,and inhibition . Endocr Rev,2005,26(2):171一202.
[9]、Tina S,Ruth R,Jasna S,et al. Expression analysis of estrogen一metabolizing enzymes in human endometrial cancer[J] .Mol Cell Endocrinol,2006,248(l/2):114一117.
[10]、Pasqualini JR , Chetrite GS.Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cance. Steroid Biochem Mol Biol,2005,93(2一5):221一236
[11]、Suzuki T, Moriya T, Ariga N, et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. BrJ Cancer 2000;82(3):518-523.
[12]、Sasano H,Suzuki T,Takeyama J,et al.17一beta一hydroxy steroid dehydrogenase in human breast and endometrial carcinoma.A new development in intracrinology(R).Oncology,2000,59(51):5一12
[13]、杨洁,韩为东,赵亚力.雌激素与乳腺癌[J].现代肿瘤医学,2007,15(3):431-43。
[14]、刘复生.肿瘤病理学[M].北京:北京医科大学中国协和医科大学出版社,1997:1648～1649。
[15]、沈坤炜,沈镇宙.乳腺癌术后系统性辅助治疗的现状和进展[J].中国癌症杂志,2003,13(4):293-295。
[16]、Santen RJ.The principle of aromatase inhibitom in the treatment of breast cancer[A] . Jonat W , Santen RJ , eds . Medical management Of breast cancer[M].Londen:Dunitz ,1991:11-27.
[17]、Lacey J r J V,Mink P J,Lubin J H,et al.Menopausal hormone replacement therapy and risk of ovarian cancer.JAMA.2002;288:334-341.
[18]、Anderson G L,Judd H L,Kaunitz A M,et al.Effects of estrogen plus progestin on gynecologic cancels and associated diagnostic procedures:The women’S health initiative randomized trial.JAMA.2003;290:1739-1748.
[19]、曹泽毅.中华妇产科学[M].北京:人民卫生出版社,2002.1797-1812.
[20]、Viqar SY,Gregory U,Samuel C,et al.Expression of receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelilal cells.Cancer Res.2001:61:6768-6776.
[21]、Russo J,Russo IH.The role of estrogen in the initiation of breast cancer[J].J Steroid Biochem Mol Biol,2006,102(1-5):89-96.
[22]、陈剑英,张波,王国斌,等.乳腺癌中雌激素诱导的细胞增殖与有丝分裂素激活蛋白激酶活性的关系[J].中华外科杂志,2004,42(22):1363-1366.
[23]、Pozzi S,Benedusi V,Maggi A,et al.Estrogen action in neuro-protection and brain inflammation[J].Ann N Y Acad Sei,2006,1089:302-323.
[24]、Misiti S,Nanni S,Fontemaggi G,et al.Induction of hTERT expression and telom erase activity by estrogens in human ovary epithelium cells.Mol Cell Biol,2000,20(11):3764-3771.
[25]、Devanesan P,Todorovic R,Zhao J,et al.Catechol estrogen conjugates and DNA adducts in the kidney of male Syriall golden hamsters treated with 4-hydmxyestradiol: potential biomarker for estrogen-initiated cancer.Carcinogenesis,2001,22:489-497
[26]、Utsumi T, Yoshimura N, Takeuehi S, et al. Elevated steroid sulfatase expression in breast cancers[J]..Steroid Biochem Mol Biol,2000,73(3-4):141-145.
[27]、Miyoshi Y,Ando A,Hasegawa S,et al. High expression of steroid sulfatase mRNA predicts Poor Prognosis in Patients with estrogen receptor-Positive breast Cancer .Clin Cancer ReS,2003,9(6):2288-2293.
[28]、Foster PA,Chander SK,Newman SP,et al.A new therapeutic strategy against hormone-dependent breast cancer:the pre-clinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res,2008,14(20):6469-6477
[29]、Evans TR,Rowlands MG,Law M,et al. Intratumoral oestrone sulphatas activity as a prognostic marker in human breast carcinoma.Br J Cancer 1994,69(3):555-561
[30]、Evans TR,Rowlands MG,Powles TJ.Post menopausal estrogen synthesis and metabolism:alterations caused by aromatase inhibitors used for the treatment of breast cancer. Steroid Biochem,1990;35(3-4):355-366
[31]、Nakata T, Takashima S, Shiotsu Y, et al. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. Steroid Biochem Mol Biol,2003,86(3-5):45-460.
[32]、Santner SJ,Feil RD,SantenRJ.In situ estrogen production via estrone su1phatase pathway in breast tumors:relative importance versus aromatase pathway. J Clin Endoerinol Metab,1984,59(1):29-33
[33]、J.L.Falany,R.Azziz.C.N.Falany,Identification and characterization of cytosolic sulfortransferases in normal human endometrim Chem-biol.Interract.1998 (109):329-339.
[34]、Her CH,Aksoy IA,Kimura S,et al.Human estrogen sulfotransferase gene(STE):cloning,structure,and chromosomal localization.Genomics,1995,29:16-23.
[35]、Kapoor&Nimmagadda D,Sheng JJ.Cellular localization studies on human estrogen sulfotransferase SULT1 E I in human embryonic kidney 293 cells.Drug Metab Dispos.2007;35(1):l7-20.
[36]、Schrag ML,Donghui Cui,RushmoreT.H,et al. Sulfotransferase 1 E l is a low Km isoform mediating the 3-o-sulfation of ethinyl estradiol.Drug Metabolism and Disposition. 2004;32:1299-1303.
[37]、文慧,等雌激素硫酸转移酶和BINI蛋白在乳腺癌组织中的基因表达及其意义《癌症》Chinese Journal of Cancer ,2004,23,(11):1302-1305.
[38]、Falany JL,Macrina N,Falany CN,Regulation of MCF-7 breast cancer cell growth by 13-estradiol sulfation.Breast Cancer Res Tr, 2002 ;74:167-176.
[39]、Utsunomiya H,Ito K,Suzuki T,et al.Steriod sulfatase and estrogen sulfotransferase in human endmetrial carcinoma.Clin.Cancer Res.2004;1 0:5850-5856.
[40]、Smuc T,Rupreht R,Sinkovec J,et al.Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrin01.2006;248(1-21):114-7.
[41]、Ishibashi H,Suzuki T,Suzuki S.Estogen inhibits cell proliferation through in situ production in human thymoma.Clincal Cancer Res 2005;11(18):6495-6504.
[42]、Reich O, Singer C, Hudelist G, et al.Estrogen sulfotransferase expression in endometrial stromal sarcomas:an immunohistochemical study.Pathol Res Pract. 2007;203(2):85-87.
[43]、Foster PA,Newman SP,Chander SK,et al.In vivo efficacy of STX213,a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy[J].Clin Cancer Res,2006,12(18):5543-5549
[44]、Foster PA,Chander SK,Parsons MF,et al.Efficacy of three potent steroid sulfatase inhibitors: Pre- clinical investigations for their use in the treatment of hormone- dependent breast cancer. Breast Cancer Res Treat,2008, 111(l):129-138
[45]、Chander SK,Foster PA,Leese MP,et al.In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer,2007,96(9): 1368-1376.
[46]、Foster PA,Ho YT,Newman SP,et al.2-Me0EZbisMATE and 2-EtE2bisMATE indue cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat,2008, 111(2):251-260.
[47]、Foster PA,Newman SP,Chander SK,et al.A newt herapeutic strategy against hormone一dependent breast cancer:the Preclinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res,2008,14(20):6469-6477.
[2] Vihko R, and Apter D. Endogenous steroids in the pathophysiology of breast cancer. CRC. Crit. Rev. Oncol. Hematol, 1989(9): 1–16.
[3] Rose C, Thorpe SM, Mouridsen, H T, Andersen J A,et al. Anti-oestrogen retreatment of post menopausal women with primary high risk breast cancer. Breast Cancer Res. Treat, 1983(3): 77–84.
[4] Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved inestrogen formation and transformation in human breast cancer. Steroid Biochem Mol Biol 2005,93(2-5):221-236.
[5] Evans TR,Rowlands MG,Law M,et al. Intratumoral oestrone sulphatas activity as a prognostic marker in human breast carcinoma .Br J Cancer 1994,69(3):555-561
[6] Evans TR, Rowlands MG, Powles TJ.Post menopausal estrogen synthesis and metabolism:alterations caused by aromatase inhibitors used for the treatment of breast cancer. Steroid Biochem,1990,35(3-4):355-366
[7] Utsumi T, Yoshimura N, Takeuehi S, et al.Elevated steroid sulfatase expression in breast cancers.Steroid Biochem Mol Biol,2000,73(3-4):141-145.
[8] Pasqualini JR.Differential effects of progestins on breast tissue enzymes. Maturitas,2003,46(Suppl 1):S45-54
[9] Nakata, Takashima S,Shiotsu Y. Role of steroid sulfatase in local Formation of estrogen in post-menopausal breast cancer patients.Steroid Biochem Mol Biol,2003,86(3-5):455-460
[10] Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, andestrone sulfate and evaluation of sulfatase and aromatase activities in pre- andpostmenopausal breast cancer patients. Clin Endocrinol Metab 1996 ;81(4):1460-1464.
[11] Luu-the V, Tremblay P, Labrie F. Characterization of type 12 17beta-hydroxysteroiddehydrogenase, an isoform of type 3 17beta-hydroxysteroiddehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006;20(2):437-443.
[12] Suzuki T, Moriya T, Ariga N, et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br Cancer 2000;82(3):518-523.
[13] Song D, Liu G, Luu-the V, et al.Expression of aromatase and 17beta-hydroxysteroiddehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. Steroid Biochem Mol Biol 2006;101(2-3):136-144.
[14] Miyoshi Y, Ando A,Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts Poor Prognosis in Patients with estrogen receptor-Positive breast Cancer. Clin Cancer ReS,2003;9(6):2288-2293.
[15] Foster PA,Chander SK,NewmanSP,et al. A new therapeutic strategy against hormone-dependent breast cancer:the pre-clinical development of a dual aromatase and sulfatase inhibitor .Clin Cancer Res, 2008,14(20):6469-6477
[16] Suzuki M,Ishida H,Shiotsu Y,et al.Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. Steroid Biochem Mol Biol 2009;113(3-5):195-201.
[17] Adajei AA , weinshibum RM . Catecholestrogen sulfation : possible role in carcinogenesis.Biochem Biophys Res Common.2002;292:
[18] Falany JL,MacrinaN,Falany CN.Regulation of MCF-7 breast cancer cell growth byβ-estrdiol sulfation.Breast Cancer RES Tr.2002;74:167-176
[19] YingHUI, ShinYASUDA, Ming-Yin LIU, et al.On the Sulfationand Methylation of Cateehol estrogens in Human Mammary epithelial Cells and Breast Cancer Cells.Bio Pharm.Bull.2008;4(3 1):769-773
[20] Schrag ML,Donghui Cui,Rushmore T.Het al.Sulfotransferase lEl is a low Km isoform mediating the 3-0-sulfation of ethinyl. Drug Metabolism and Disposition. 2004,32:1299-1303.
[21] Wild MJ, Rudland PS, Back DJ. Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal ( Huma 7 ) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.J steriod BiocheMol Biol,1991,39:535-543
[22] Chetrite, G., Le Nestour, E., and Pasqualini, J. R. Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020). Steroid Biochem. Mol. Biol.,1998;66: 295–302,.
[23] Falany, JL, and Falany, CN, Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res. 1996;56: 1551–1555.
[24] Takashi Suzuki, Taisuke Nakata, Yasuhiro Miki, et al. Estrogen Sulfotransferase and Steroid Sulfatase in Human Breast Carcinoma.Cancer Res 2003;63:2762-2770.
[25] Pasqualini JR, Chetrite GC, Blacker, et al.Concentrations of estrone,estradioland estrone sulfate and evaluation of sulfatase and aomatase aetivities in Pre-and-Post menopausal breast cancer patients. Clin Endoerinol Metab.1996;81:1460-1464
[26] BulunSE, Yangs, FangZ, et al.Estrogen Production and metabolism endometriosis Mol Hum Re Poul.2002;8(12)1103-1110
[1]、Yang L.Parkin DM,Ferlav J,et al.Eimates of cancer incidence in China for 2000 and projections for 2005 [J].Cancer Epidemiol Biomarkers Prev,2005,14(1):243-250.
[2]、陈剑英,张波,王国斌,等.乳腺癌中雌激素诱导的细胞增殖与有丝分裂素激活蛋白激酶活性的关系.中华外科杂志,2004,42(22):1363-1366.
[3]、Pozzi S,Benedusi V,Maggi A,et al.Estrogen action in neuro—protection and brain inflammation.Ann N Y Acad Sei,2006,1089:302-323.
[4]、Strehlow K,Rotter S,Wassmann S,et al.Modulation of antioxidant enzyme expression and function by estrogen. Circ Res,2003,93(2):170-177.
[5]、Benvenuti S,Luciani P,Vannelli GB,et al.Estrogen and selectire estrogen receptor modulators exert neur0pr0tective effects and stimulate the expression of selective Alzheim er's disease indicator1,a recently discovered antiapoptotie gene,in hum an neuroblast long—term cell cultures.Clin Endocrinol Metab,2005,90(3):1775-1782.
[6]、Misiti S,Nanni S,Fontemaggi G,et al.Induction of hTERT expression and telom erase activity by estrogens in human ovary epithelium cells.Mol Cell Biol,2000,20(11):3764—3771.
[7]、Geisler J.Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. Steroid Biochem Mol Biol,2003,86(3一5):245一253.
[8]、Reed MJ,Purohit A,Woo LW,et al.Steroid sulfatase:molecular biology,regulation,and inhibition . Endocr Rev,2005,26(2):171一202.
[9]、Tina S,Ruth R,Jasna S,et al. Expression analysis of estrogen一metabolizing enzymes in human endometrial cancer[J] .Mol Cell Endocrinol,2006,248(l/2):114一117.
[10]、Pasqualini JR , Chetrite GS.Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cance. Steroid Biochem Mol Biol,2005,93(2一5):221一236
[11]、Suzuki T, Moriya T, Ariga N, et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. BrJ Cancer 2000;82(3):518-523.
[12]、Sasano H,Suzuki T,Takeyama J,et al.17一beta一hydroxy steroid dehydrogenase in human breast and endometrial carcinoma.A new development in intracrinology(R).Oncology,2000,59(51):5一12
[13]、杨洁,韩为东,赵亚力.雌激素与乳腺癌[J].现代肿瘤医学,2007,15(3):431-43。
[14]、刘复生.肿瘤病理学[M].北京:北京医科大学中国协和医科大学出版社,1997:1648～1649。
[15]、沈坤炜,沈镇宙.乳腺癌术后系统性辅助治疗的现状和进展[J].中国癌症杂志,2003,13(4):293-295。
[16]、Santen RJ.The principle of aromatase inhibitom in the treatment of breast cancer[A] . Jonat W , Santen RJ , eds . Medical management Of breast cancer[M].Londen:Dunitz ,1991:11-27.
[17]、Lacey J r J V,Mink P J,Lubin J H,et al.Menopausal hormone replacement therapy and risk of ovarian cancer.JAMA.2002;288:334-341.
[18]、Anderson G L,Judd H L,Kaunitz A M,et al.Effects of estrogen plus progestin on gynecologic cancels and associated diagnostic procedures:The women’S health initiative randomized trial.JAMA.2003;290:1739-1748.
[19]、曹泽毅.中华妇产科学[M].北京:人民卫生出版社,2002.1797-1812.
[20]、Viqar SY,Gregory U,Samuel C,et al.Expression of receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelilal cells.Cancer Res.2001:61:6768-6776.
[21]、Russo J,Russo IH.The role of estrogen in the initiation of breast cancer[J].J Steroid Biochem Mol Biol,2006,102(1-5):89-96.
[22]、陈剑英,张波,王国斌,等.乳腺癌中雌激素诱导的细胞增殖与有丝分裂素激活蛋白激酶活性的关系[J].中华外科杂志,2004,42(22):1363-1366.
[23]、Pozzi S,Benedusi V,Maggi A,et al.Estrogen action in neuro-protection and brain inflammation[J].Ann N Y Acad Sei,2006,1089:302-323.
[24]、Misiti S,Nanni S,Fontemaggi G,et al.Induction of hTERT expression and telom erase activity by estrogens in human ovary epithelium cells.Mol Cell Biol,2000,20(11):3764-3771.
[25]、Devanesan P,Todorovic R,Zhao J,et al.Catechol estrogen conjugates and DNA adducts in the kidney of male Syriall golden hamsters treated with 4-hydmxyestradiol: potential biomarker for estrogen-initiated cancer.Carcinogenesis,2001,22:489-497
[26]、Utsumi T, Yoshimura N, Takeuehi S, et al. Elevated steroid sulfatase expression in breast cancers[J]..Steroid Biochem Mol Biol,2000,73(3-4):141-145.
[27]、Miyoshi Y,Ando A,Hasegawa S,et al. High expression of steroid sulfatase mRNA predicts Poor Prognosis in Patients with estrogen receptor-Positive breast Cancer .Clin Cancer ReS,2003,9(6):2288-2293.
[28]、Foster PA,Chander SK,Newman SP,et al.A new therapeutic strategy against hormone-dependent breast cancer:the pre-clinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res,2008,14(20):6469-6477
[29]、Evans TR,Rowlands MG,Law M,et al. Intratumoral oestrone sulphatas activity as a prognostic marker in human breast carcinoma.Br J Cancer 1994,69(3):555-561
[30]、Evans TR,Rowlands MG,Powles TJ.Post menopausal estrogen synthesis and metabolism:alterations caused by aromatase inhibitors used for the treatment of breast cancer. Steroid Biochem,1990;35(3-4):355-366
[31]、Nakata T, Takashima S, Shiotsu Y, et al. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. Steroid Biochem Mol Biol,2003,86(3-5):45-460.
[32]、Santner SJ,Feil RD,SantenRJ.In situ estrogen production via estrone su1phatase pathway in breast tumors:relative importance versus aromatase pathway. J Clin Endoerinol Metab,1984,59(1):29-33
[33]、J.L.Falany,R.Azziz.C.N.Falany,Identification and characterization of cytosolic sulfortransferases in normal human endometrim Chem-biol.Interract.1998 (109):329-339.
[34]、Her CH,Aksoy IA,Kimura S,et al.Human estrogen sulfotransferase gene(STE):cloning,structure,and chromosomal localization.Genomics,1995,29:16-23.
[35]、Kapoor&Nimmagadda D,Sheng JJ.Cellular localization studies on human estrogen sulfotransferase SULT1 E I in human embryonic kidney 293 cells.Drug Metab Dispos.2007;35(1):l7-20.
[36]、Schrag ML,Donghui Cui,RushmoreT.H,et al. Sulfotransferase 1 E l is a low Km isoform mediating the 3-o-sulfation of ethinyl estradiol.Drug Metabolism and Disposition. 2004;32:1299-1303.
[37]、文慧,等雌激素硫酸转移酶和BINI蛋白在乳腺癌组织中的基因表达及其意义《癌症》Chinese Journal of Cancer ,2004,23,(11):1302-1305.
[38]、Falany JL,Macrina N,Falany CN,Regulation of MCF-7 breast cancer cell growth by 13-estradiol sulfation.Breast Cancer Res Tr, 2002 ;74:167-176.
[39]、Utsunomiya H,Ito K,Suzuki T,et al.Steriod sulfatase and estrogen sulfotransferase in human endmetrial carcinoma.Clin.Cancer Res.2004;1 0:5850-5856.
[40]、Smuc T,Rupreht R,Sinkovec J,et al.Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrin01.2006;248(1-21):114-7.
[41]、Ishibashi H,Suzuki T,Suzuki S.Estogen inhibits cell proliferation through in situ production in human thymoma.Clincal Cancer Res 2005;11(18):6495-6504.
[42]、Reich O, Singer C, Hudelist G, et al.Estrogen sulfotransferase expression in endometrial stromal sarcomas:an immunohistochemical study.Pathol Res Pract. 2007;203(2):85-87.
[43]、Foster PA,Newman SP,Chander SK,et al.In vivo efficacy of STX213,a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy[J].Clin Cancer Res,2006,12(18):5543-5549
[44]、Foster PA,Chander SK,Parsons MF,et al.Efficacy of three potent steroid sulfatase inhibitors: Pre- clinical investigations for their use in the treatment of hormone- dependent breast cancer. Breast Cancer Res Treat,2008, 111(l):129-138
[45]、Chander SK,Foster PA,Leese MP,et al.In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer,2007,96(9): 1368-1376.
[46]、Foster PA,Ho YT,Newman SP,et al.2-Me0EZbisMATE and 2-EtE2bisMATE indue cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat,2008, 111(2):251-260.
[47]、Foster PA,Newman SP,Chander SK,et al.A newt herapeutic strategy against hormone一dependent breast cancer:the Preclinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res,2008,14(20):6469-6477.